The Authors’ Reply

Excerpt

We read with interest the letter by Golomb et al.,[1] regarding our recent review article on statin-related myopathy.[2] Our purpose was to provide an up-to-date, comprehensive review of potential factors that may increase the myopathic risk of patients treated with HMG-CoA reductase inhibitors (‘statins’). Because of the widespread use of statins, this has long been, and still remains, a widely discussed topic. Given the vast number of publications on the safety profile and potential side effects of statins, the presentation of the tables and figures that summarize the major points of our article may be viewed as complementary to previously published work,[3,4] including, but certainly not limited to, the excellent article by Golomb and Evans.[5] We feel that an additional contribution of our paper is putting the theoretical points into a clinical perspective, as we summarize recent guidelines and current evidence regarding the diagnostic evaluation and management of statin-induced myopathy in our figure 2. …